Core Viewpoint - The company, Kewang Pharmaceutical, has a diverse product portfolio covering various therapeutic areas, including pediatric and adult respiratory medications, indicating a strong presence in the respiratory and general health sectors [1] Product Coverage - The company's products span several treatment areas: children's medications, digestive system, respiratory and cold system, rheumatology, cardiovascular system, gynecology, and general health [1] - In the respiratory and cold treatment area, the company offers a range of pediatric medications, including: - Xiaoer Feire Kechuan Oral Liquid/Granules - Xiaoer Huatan Zhike Granules - Xiaoer Keshuan Ling - Xiaoer Chaigui Antipyretic Granules - Ibuprofen Suspension Drops/Liquid - Roxithromycin Granules - Azithromycin Dry Suspension [1] - For adult respiratory medications, the company provides: - Ganmaoling Capsules/Granules - Compound Acetaminophen and Amantadine Capsules/Granules/Tablets - Ambroxol Hydrochloride Oral Solution - Roxithromycin Dispersible Tablets/Capsules - Pudilan Anti-inflammatory Tablets - Compound Honeysuckle Granules - Azithromycin Capsules/Tablets [1]

Core Points - The company, Kew Flower Pharmaceutical Group Co., Ltd., announced a board resolution on November 18, 2025, to allocate up to 50 million yuan for product research and development, focusing on traditional Chinese medicine, generic drug consistency evaluation projects, and expanding indications for existing products [1][2] - The board meeting was conducted via telecommunication, with all 9 participating directors voting in favor of the proposal, indicating unanimous support for the R&D initiatives [1] - The R&D investment aims to optimize the product structure and enhance the company's core competitiveness, reinforcing its long-term development strategy in the pharmaceutical sector [2] Summary by Categories R&D Investment - The company plans to invest no more than 50 million yuan in R&D, targeting three main areas: traditional Chinese medicine, generic drug consistency evaluation, and expanding indications for existing products [1] - This investment is intended to enrich the product pipeline and strengthen the company's long-term growth potential [1][2] Board Meeting Details - The fifth board's thirteenth meeting was held on November 18, 2025, with all 9 directors participating and voting unanimously in favor of the R&D proposal [1] - The decision falls within the board's authority and does not require shareholder approval, allowing management to control the project’s progress [1] Strategic Focus - Kew Flower Pharmaceutical continues to focus on its core pharmaceutical business, with this R&D funding expected to enhance its position in the innovation of traditional Chinese medicine and the quality improvement of generic drugs [2]

Core Viewpoint - Kew Flower Pharmaceutical announced the convening of its 13th board meeting of the 5th session on November 18, 2025, to discuss product research and development initiatives [1] Company Summary - For the first half of 2025, Kew Flower Pharmaceutical's revenue composition was 99.61% from the pharmaceutical industry and 0.39% from other businesses [1] - As of the report date, Kew Flower Pharmaceutical has a market capitalization of 8.7 billion yuan [1]

Group 1 - The company, Kew Flower Pharmaceutical (002737.SZ), announced a plan to invest up to 50 million yuan for the development of traditional Chinese medicine with the same name and formula, generic drug projects aligned with consistency evaluation, and research to expand indications for existing products [1] - The management has been authorized to oversee the progress and specific matters related to the project development [1] - This initiative aims to enrich the product pipeline and strengthen the company's long-term development momentum [1]

Group 1 - The company, Kew Flower Pharmaceutical (002737.SZ), announced a plan to invest up to 50 million yuan for the development of traditional Chinese medicine with the same name and formula, generic drug projects aligned with consistency evaluation, and research to expand indications for existing products [1] - The management has been authorized to oversee the progress and specific matters related to the project development [1] - This initiative aims to enrich the product pipeline and strengthen the company's long-term development momentum [1]

Core Viewpoint - The company has approved a funding of up to 50 million yuan for various drug development projects, indicating a strategic focus on expanding its product offerings and enhancing its research capabilities [1] Group 1: Product Development Initiatives - The company will initiate research and development for traditional Chinese medicine with the same name and formula [1] - The company plans to develop generic drugs that are equivalent to the consistency evaluation projects [1] - There will be efforts to expand existing products by adding new indications [1] Group 2: Management and Oversight - The management team has been authorized to oversee the progress and specific matters related to the R&D projects [1] - The decision falls within the board's authority and does not require shareholder approval [1]

会议应参加表决董事 9 人，实际参加表决董事 9 人。本次会议召集、召开程 序符合《公司法》及相关法律、法规以及《公司章程》之规定。会议决议合法有 效。 二、董事会会议审议情况 证券代码：002737 证券简称：葵花药业 公告编号：2025-075 葵花药业集团股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届董事 会第十三次会议于 2025 年 11 月 18 日上午 9 时以通讯表决方式召开。会议由公 司董事长关玉秀女士召集，会议通知及议案于 2025 年 11 月 13 日通过电子邮件 形式发出。 三、备查文件 1、公司第五届董事会第十三次会议决议 特此公告。 1、审议通过《关于产品研发立项的议案》 为丰富产品管线，蓄力长期发展势能，同意公司自筹资金不超过 5,000 万元 立项开展中药同名同方药研发、化药仿制药视同一致性评价项目研发、现有产品 增加适应症研发工作。授权经营管理层对项目研发进度等具体事项进行管控。 表决结果： ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-074 葵花药业集团股份有限公司 | 序 | | | | 金额 | | | 预期年化收 | 资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 签约机构 | 产品名称 | 产品类型 | | 起息日 | 到期日 | | | | 号 | | | | （万元） | | | 益率 | 来源 | | | 招商银行 | 招商银行聚益生金系 | 固定收益类 | | | | | 闲置 | | 1 | 哈尔滨平 | 列公司（35 天）B 款 | 非保本浮动 | 20,000.00 | 2025.11.14 | 2025.12.19 | | 2.1% 自有 | | | 房支行 | 理财计划 | 收益型 | | | | | 资金 | | | | 合计 | | 20,000.00 | | | | | 注：公司与上述签约机构不存在关联关系。 二、投资风险及风险控制措施 1 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性 ...

Group 1: Company Announcements - 合富中国's stock price increased by 256.29% over 14 trading days, significantly outperforming the industry and Shanghai Composite Index, leading to a suspension for verification starting November 17 [1] - 工业富联's GB300 achieved mass production in Q3, with improved yield and testing efficiency, positively impacting Q4 gross margin [2] - 天孚通信's controlling shareholder plans to transfer 8.5 million shares, representing 1.09% of total equity, due to personal funding needs [4] - 璞泰来 plans to invest 7.6 billion yuan in a new integrated film coating project, aiming to meet growing demand in the battery and energy storage sectors [5] - 电投能源 intends to acquire 100% of Baiyin Hua Coal Power for 11.149 billion yuan, financing through share issuance and cash [6] - 中微公司 reported that a shareholder completed a reduction of 12.52 million shares, totaling 3.351 billion yuan [7] - 瑞德智能 plans to invest 10 million yuan in a leading company in the power plant robotics sector [8] - 盘古智能 aims to acquire control of a petrochemical company by purchasing 11.97% of its shares for 24.64 million yuan [9] - 泰达股份 signed a memorandum for a waste-to-energy project in Egypt [10] - 杭氧股份 is set to establish a venture capital fund focusing on low-temperature technology and nuclear fusion [11] Group 2: Financial Performance and Regulatory Approvals - 复星医药's subsidiary received FDA approval for a biosimilar drug, with applications pending in China and Europe [21] - 长春高新 received approval for a clinical trial of a new growth hormone drug, with no similar products currently available in China [20] - 海辰药业 obtained a drug registration certificate for a new injection product [22] - 上海机场 reported a 12.46% year-on-year increase in passenger throughput for October [23] Group 3: Shareholder Actions - 深桑达 A plans to publicly transfer 80% of a subsidiary's shares with a minimum price of 1.857 billion yuan [12] - 中电港's major shareholder reduced its stake by 1% between October 31 and November 13 [15] - 康龙化成's major shareholders plan to collectively reduce their holdings by up to 1.5% [16] - 科兴制药's controlling shareholder intends to transfer 5% of its shares [17]

Group 1 - The core point of the article is that Kew Flower Pharmaceutical Co., Ltd. has received a drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Powder from the National Medical Products Administration [1] - Kew Flower Pharmaceutical's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 99.61% of total revenue, while other businesses contribute only 0.39% [1] - As of the report date, Kew Flower Pharmaceutical has a market capitalization of 8.8 billion yuan [1]